AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

TRASTUZUMAB EMTANSINE

8 registrations across 4 African markets— 8 active

Markets with TRASTUZUMAB EMTANSINE

Recent registrations

Brand / ProductMarketHolderStatusExpires
Kadcyla
Solution for injection in vial
🇿🇲ZambiaRoche ProductsactiveMar 2031
kadcyla
Solution For Infusion
🇿🇲ZambiaRoche ProductsactiveJan 2031
Kadcyla Powder for Concentrate for Solution for Infusion 100 mg**
Powder for concentrate for solution for infusion
🇳🇬NigeriaRoche Products LimitedactiveMay 2028
Kadcyla Powder for Concentrate for Solution for Infusion 160 mg**
Powder for concentrate for solution for infusion
🇳🇬NigeriaRoche Products LimitedactiveMay 2028
Kadcyla 100 mg
Powder For Concentrate For Solution For Infus
🇰🇪KenyaF. Hoffman-La Roche LtdactiveApr 2028
Kadcyla 160 mg
Powder For Concentrate For Solution For Infus
🇰🇪KenyaF. Hoffmann-La Roche Ltd.activeApr 2028
KADCYLA® 100MG PPS PERF IV BTE(1FL) ROCHE PRODUCTS
Poudre pour solution à diluer
🇲🇬MadagascarROCHE PRODUCTS (Pty) LTDactive
KADCYLA® 100MG PPS PERF IV BTE(1FL) ROCHE PRODUCTS
Poudre pour solution à diluer
🇲🇬MadagascarROCHE PRODUCTS (Pty) LTDactive

TRASTUZUMAB EMTANSINE in Africa — Regulatory Overview

TRASTUZUMAB EMTANSINE is registered across 4 African markets with 8 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Kenya, Madagascar, Nigeria, Zambia. AfricaRegulatory refreshes this data daily from official government sources.

Of the 8 registrations, 8 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.